Phase III DAS181 Lower Tract PIV Infection in Immunocompromised Subjects (Substudy: DAS181 for COVID-19): RCT Study

Launched by ANSUN BIOPHARMA, INC. · Jan 16, 2019

Keywords

ClinConnect Summary

This clinical trial is studying the use of a medication called DAS181 to treat lower respiratory tract infections caused by parainfluenza viruses in patients with weakened immune systems. There is also a part of the study that focuses on patients who are severely affected by COVID-19. The goal is to see if DAS181 can help improve their condition and recovery.

To participate, patients must be immunocompromised—this means their immune system is not working well due to factors like past organ transplants or ongoing cancer treatment—and need supplemental oxygen for breathing difficulties. They should also have a confirmed lower respiratory infection. Participants will be selected based on specific criteria, and they'll need to provide informed consent before joining. Those who qualify can expect to receive close monitoring during the trial, and their health will be assessed regularly. It’s important to note that certain patients, such as those on hospice care or with severe organ failures, will not be eligible for this study.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. At the time of randomization, requires supplemental oxygen ≥2 LPM due to hypoxemia.
• 2. Immunocompromised, as defined by one or more of the following:
• • Received an autologous or allogeneic hematopoietic stem cell transplantation (HSCT) at any time in the past
• • Received a solid organ transplant at any time in the past
• • Has been or is currently being treated with chemotherapy for hematologic malignancies (e.g., leukemia, myeloma, lymphoma) and/or solid tumor malignancies (e.g., lung, breast, brain cancer) at any time in the past
• • Has an immunodeficiency due to congenital abnormality (only applicable to subjects age \< 18 years old) or pre-term birth (only applicable to subjects age ≤ 2 years old)
• • 3. Has, within 3 days prior to randomization, a confirmed LRTI with a sialic acid dependent respiratory virus
• 4. If female, subject must meet one of the following conditions:
• • Not be of childbearing potential or
• • Be of childbearing potential and have a negative urine/serum pregnancy test and agrees to practice an acceptable method of contraception
• • 5. Non-vasectomized males are required to practice effective birth control methods
• • 6. Capable of understanding and complying with procedures as outlined in the protocol
• • 7. Provides signed informed consent prior to the initiation of any screening or study-specific procedures
• For COVID-19 sub study:
• • 1. Be ≥18 years of age
• • 2. Provide adequate medical history to permit accurate stratification (but health status may be healthy, high-risk conditions, or immunocompromised).
• • 3. Prior to SARS CoV 2 infection, has the ability to carry out self-care activities of daily living (basic ADL)
• • 4. Have lower respiratory tract infection (LRTI) confirmed by CT imaging, with or without contrast, to involve at least 2 lobes of the lung.
• • 5. Has laboratory-confirmation of the presence of SARS CoV 2 in the respiratory tract by at least one of the following samples
• • 6. Satisfy inclusion criteria #1, 4, 5, 6, 7 of the main study
• Exclusion Criteria:
• • 1. Subjects may not be on hospice care or, in the opinion of the investigator, have a low chance of survival during the first 10 days of treatment
• • 2. Subjects with Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST), or Alkaline Phosphatase (ALP) ≥3x ULN and Total Bilirubin (TBILI) ≥2x ULN Note: Subjects with ALT/AST/ALP ≥ 3x ULN AND TB ≥2x ULN that have been chronically stable (for \>1 year on more than one assessments) due to known liver pathology including malignancy (primary or metastasis), chronic medications, transplantation, or chronic infection will not be excluded
• • 3. Female subjects breastfeeding or planning to breastfeed at any time through 30 days after the last dose of study drug
• • 4. Subjects taking any other investigational drug used to treat pulmonary infection.
• • 5. Psychiatric or cognitive illness or recreational drug/alcohol use that, in the opinion of the principal investigator, would affect subject safety and/or compliance
• • 6. Subjects with known hypersensitivity to DAS181 and/or any of its components
• 7. Subjects with severe sepsis due to either their baseline SAD-RV infection or a concurrent viral, bacterial, or fungal infection and meet at least one of the following criteria:
• • Has evidence of vital organ failure outside of the lung (e.g., liver, kidney)
• • Requires vasopressors to maintain blood pressure
• For COVID-19 sub study:
• • 1. Subjects requiring invasive mechanical, Bi-PAP or CPAP ventilation at randomization.
• • 2. Subjects receiving any other investigational or empiric treatment for SARS-2-CoV (either as part of a clinical trial or under emergency approval (approved agents for the management of symptoms, e.g., fever, are permitted).
• • 3. Subjects who are known HIV-positive (and not undetectable at most recent HIV RNA assessment)
• • 4. Subjects who are currently taking immunomodulating biologics (e.g, interferons, interleukin)
• 5. Subjects with severe sepsis due to either their SARS-CoV-2 infection or a concurrent viral, bacterial, or fungal infection and meeting at least one of the following criteria:
• • Have evidence of vital organ failure outside of the lung (e.g., liver, kidney)
• • Require vasopressors to maintain blood pressure
• • 6. Subjects meeting exclusion criteria #2, 3, 5 and 6 of the main study